Maria Thacker, President & CEO of Georgia Bio, Elected as New Board Chair for the Council of State Bioscience Associations (CSBA)

The Council of State Bioscience Associations (CSBA) today announced the election of new board members to its Board of Directors for the next two-year term (2022-2023). CSBA also announced new board leadership, including new Chair of the Board of Directors, Maria Thacker, President & CEO of Georgia Bio.


“We are thrilled to announce our new slate of incredibly accomplished and esteemed board leaders for the next exciting phase of CSBA,” said Michele Oshman, Executive Director of Council of State Bioscience Associations (CSBA) and Vice President of External Affairs at the Biotechnology Innovation Organization (BIO). “From the global threats of pandemics and climate change to the growing impact of bioscience on local jobs and economies, our industry faces many important challenges today. We look forward to continuing to work together across our new board leadership, members, and stakeholders to confront these threats and expand opportunities for innovation.”


CSBA is pleased to announce the following leaders and members of the board of directors for the 2022-2023 term:


• Maria Thacker, Board Chair
President & CEO, Georgia Bio
• Kelvyn Cullimore, Board Member
President & CEO, BioUtah
• Michael Fleming, Board Member
President, Delaware Bio
• Laura Gunter, Board Member
President, NCBIO
• Sonia Hall, Board Member
President & CEO, BioKansas
• Debbie Hart, Past Chair
President & CEO, BioNJ
• Liisa Bozinovic, CSBI Representative
Executive Director, Oregon Bio

The new leaders and members of the board of directors will join existing members serving for the 2021-2022 term:


• John Conrad, Board Member
President & CEO, iBIO
• Mike Guerra, Board Member
President & CEO, California Life Sciences
• Dawn Hocevar, Board Member
President & CEO, BioCT


“I am honored to be the new CSBA Board Chair and pledge to continue elevating the critical work of state biotechnology associations nationwide,” said Maria Thacker, Board Chair, CSBA and President & CEO, Georgia Bio. ”Our associations play a central role in championing the groundbreaking work of the biotechnology sector as we innovate for human health discoveries, agricultural advancements, and environmental sustainability.”

“It has been my honor to serve as the CSBA Board Chair over these last two years,” said Debbie Hart, Past Chair, CSBA and President & CEO, BioNJ. “Our state associations have faced immense challenges on the policy arena as well as an unprecedented global pandemic. I am proud of what we have collectively accomplished in helping to stave off grave policy proposals, offering unique educational opportunities, and supporting our Members, all despite operating remotely in a time of immense change for our country. I am delighted to see the very talented Maria Thacker take over as the new CSBA Chair and look forward to supporting her in that role and to our ongoing collaboration on behalf of our industry.”

About The Council of State Bioscience Associations


The Council of State Bioscience Associations (CSBA) is a confederation of state-based, nonprofit trade organizations each governed by its own board of directors convened by the Biotechnology Innovation Organization (BIO). The common mission of the members of the CSBA is to promote public understanding and to advocate for public policies that support patient access to lifesaving therapies and the responsible development of the bioscience industry.

Georgia’s Life Sciences Momentum is Getting Noticed Nationally.

August 21, 2026
Genetic Engineering & Biotechnology News (GEN) has named Georgia #4 among its “Next 5 States” for emerging U.S. biopharma clusters . The article highlights UCB’s planned $2 billion investment at in Gwinnett County, Micron Biomedical’s new Alpharetta facility, Manus Bio’s expansion in Augusta, Science Square, Emory University, the CDC — and Georgia Life Sciences’ 10-year Life Sciences Roadmap . This recognition is exciting. But even more importantly, it validates the work happening across our entire ecosystem — and perfect momentum as we head into the 2026 Georgia Life Sciences Summit next week. Read more by visiting: Next 10 U.S. Biopharma Clusters

BIO Supports PDUFA VIII Commitment Letter and Urges Timely Reauthorization

August 17, 2026
Biotechnology Innovation Organization (BIO) Senior Vice President of Science & Regulatory Affairs Annetta Beauregard issued the following statement on the release of the Prescription Drug User Fee Act (PDUFA) VIII commitment letter: “For more than 30 years, PDUFA has helped deliver hundreds of new medicines to American patients. As a lead industry negotiator for the PDUFA VIII agreement, BIO supports the PDUFA VIII commitment letter and its strengthening of regulatory review, advancing innovation, and helping deliver safe and effective treatments to patients. “Specifically, the PDUFA VIII agreement includes important commitments that bolster the FDA’s core review activities, ensure accountability for predictable performance, improve financial sustainability and improve communication, transparency and efficiency. “Timely, bipartisan reauthorization of PDUFA is vital for protecting the health of Americans, strengthening U.S. competitiveness, and maintaining America’s global leadership in medical innovation. BIO is committed to working with Congress to ensure reauthorization by September 30, 2027.” The FDA has announced plans to hold a hybrid public meeting at 9am on 9/16 to discuss the proposed enhancements for the reauthorization of PDUFA for fiscal years (FYs) 2028 through 2033. Learn More about PDUFA and the PDUFA VIII commitment letter HERE .

Georgia Life Sciences Submits Comments on Medicare Drug Price Negotiation Program

August 17, 2026
Representing Georgia’s life sciences community, GLS emphasized the importance of advancing policies that improve affordability and patient access while preserving the environment necessary for continued biomedical innovation. In its comments, GLS urged CMS to maintain a framework grounded in FDA regulatory determinations and raised concerns about how certain proposed policies could affect post-approval research and development, investment in new indications, and patient access to innovative therapies. GLS also encouraged CMS to consider the broader implications for healthcare delivery, including the potential impact on patients and providers in rural and underserved communities. As federal drug pricing policy continues to evolve, Georgia Life Sciences will continue to advocate for approaches that balance affordability, access, and innovation while ensuring Georgia’s life sciences community has a voice in the policymaking process. Read Georgia Life Sciences’ full comments to CMS ( click here ).
MORE POSTS